Search

everythinglearnresearchcommunity

for

Search:↓

Skin-resident memory T cells may contribute to chronic alopecia areata and baricitinib could be a potential treatment.

5-alpha reductase inhibitors and spironolactone don't increase gynecological tumor risk, glucagon-like-peptide-1 receptor agonists may increase alopecia risk, sanitary pads can cause dermatitis, early hidradenitis suppurativa intervention is crucial for Hispanic patients, community education boosts skin cancer awareness, metformin may improve skin cancer survival, LNG-IUDs can increase acne risk, machine learning accurately detects basal cell carcinoma, JAK-inhibitors may raise miscarriage risk, inclusive skincare ads affect those with darker skin, and CCCA in Black women might involve autoimmunity.

Baricitinib improved platelet counts and alopecia in a 16-year-old with chronic immune thrombocytopenia.

Baricitinib helped treat a man's beard hair loss when steroids didn't work.

Baricitinib is effective and safe for treating severe alopecia areata, promoting significant hair regrowth.

Pediatric dermatologists have varied preferences for treating alopecia areata in children, with no standard FDA-approved treatments and some using JAK inhibitors despite risks.

Abrocitinib shows promise for treating various skin conditions beyond atopic dermatitis.

Abrocitinib may help treat alopecia areata effectively with mild side effects.

Long-term baricitinib treatment can lead to significant scalp hair regrowth in patients initially showing only eyebrow or eyelash regrowth.

Topical ruxolitinib may help some skin conditions but needs more research for alopecia areata.

Abrocitinib may effectively treat stubborn alopecia universalis.

Upadacitinib is safe and effective for treating alopecia areata and atopic dermatitis in children.

Baricitinib can cause excessive hair growth.

Abrocitinib effectively treats severe alopecia areata with significant improvement and no side effects.

Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.

A potential treatment for atopic dermatitis could be to increase PADI1 expression to improve skin barrier function.

Baricitinib helps with severe hair loss, negative-pressure therapy lowers hernia recurrence, tranexamic acid reduces bleeding, robot-assisted breast surgery may improve outcomes, and acellular dermal matrix could decrease breast reconstruction complications.

Upadacitinib can effectively regrow hair in alopecia areata patients without worsening sarcoidosis.

Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.

Baricitinib shows promise for treating alopecia areata with mild side effects.

Blocking JAK3 signaling can reverse hair loss from alopecia areata.

Upadacitinib significantly improved alopecia universalis and psoriatic arthritis in a patient.

Upadacitinib helped regrow hair in a severe alopecia areata patient but stopping treatment caused hair loss to return.

Ruxolitinib effectively and safely regrows hair in alopecia patients.

A new drug, abrocitinib, helped a child with severe hair loss regrow hair.

Baricitinib was effective in treating a patient with dermatomyositis and hair loss.

Upadacitinib may effectively treat twenty-nail dystrophy without causing pain.

JAK inhibitors may help treat certain types of hair loss, but more research is needed.

Upadacitinib and oral minoxidil improved Crohn's disease and hair regrowth in a patient.

Baricitinib quickly improved severe alopecia areata, with almost total hair regrowth in three months.